Journal Basic Info

  • Impact Factor: 0.285**
  • H-Index: 6
  • ISSN: 2638-4558
  • DOI: 10.25107/2638-4558
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Cardiovascular Medicine
  •  Pulmonary Medicine
  •  Orthopedic Sugery
  •  Allergy & Immunology
  •  Radiation Oncology
  •  Obstetrics and Gynecology
  •  Veterinary Sciences
  •  Virology

Abstract

Citation: Clin Case Rep Int. 2022;6(1):1337.DOI: 10.25107/2638-4558.1337

A Palmitoylethanolamide (PEA) and Magnesium Based Product (PEAMag) Reduces the Pain and Improves Quality of Life in Patients Affected by Acute and Chronic Pelvic Pain

Marco Rinaldi, Sebastiano Di Lena, Deborah Luccarelli and Carlo Bettocchi

Department of Urology, Western Hospital Unit “San Pio”, Italy
Department of Urology, University of Bari, Italy
Department of Pharmacy, University of Bari, Italy
Department of Urology, University of Foggia, Italy
European Society for Sexual Medicine (ESSM), Italy

*Correspondance to: Marco Rinaldi 

 PDF  Full Text Case Study | Open Access

Abstract:

Aims: To assess the analgesic efficacy of a Palmitoylethanolamide and Magnesium based product (PEAMag) on acute and chronic pelvic pain due to different causes, such as CPPS, acute and chronic prostatitis, acute and recurrent cystitis and bladder stones. Methods: A pilot, open-label, prospective, monocentric study was carried out involving 32 patients treated with PEAMag sticks administered orally sublingual for a period of 3 months. Pelvic pain was evaluated using the Visual Analogue Scale (VAS score) and Quality of Life (QoL) associated with pelvic pain using number 9 domain (Quality of Life) of the Italian version of the NIH-CPSI scale. Results: A significant and progressive reduction in pain intensity after 1 month of treatment with PEAMag (p<0.001) and after 3 months of treatment (p<0.001) and a significant improvement in Quality of Life after 1 month of treatment (p<0.0001) and after 3 months of treatment (p<0.001) was observed. The results show also improvements from one month after treatment to 3 months after treatment. Conclusion: These data highlight the potential benefit of PEAMag in patients with varying nature and intensity acute and chronic pelvic pain and confirm the good safety profile of PEA and magnesium based product.

Keywords:

Pelvic pain; PEA; Magnesium; Acute prostatitis; Chronic prostatitis; Cystitis; CPPS

Cite the Article:

Rinaldi M, Di Lena S, Luccarelli D, Bettocchi C. A Palmitoylethanolamide (PEA) and Magnesium Based Product (PEAMag) Reduces the Pain and Improves Quality of Life in Patients Affected by Acute and Chronic Pelvic Pain. Clin Case Rep Int. 2022; 6: 1337.

Search Our Journal

Journal Indexed In

Articles with Grants

Clinicopathological Characteristics of Medullary Thyroid Carcinoma with the Expression of Thyroglobulin in East – China
 Abstract  PDF  Full Text
A Comparative Analysis of Changes to Intraocular Pressure of ARDS Patients Induced by Prone Position Ventilation
 Abstract  PDF  Full Text
View More...